Semigallia SIA
- Address
- Aizputes Iela 22, 3301 Kuldīga, Latvia
Semigallia SIA - Dermatology and Psoriasis Research Center
Semigallia SIA is a specialized clinical research center dedicated to advancing treatment options for patients with moderate to severe plaque psoriasis. The center focuses exclusively on dermatological conditions, with particular expertise in conducting Phase 3 clinical trials evaluating novel systemic therapies and oral medications for chronic inflammatory skin diseases.
- Comparative efficacy studies of oral immunomodulatory agents for plaque psoriasis
- Long-term safety and tolerability assessments of investigational dermatologic therapies
- Evaluation of treatment durability and sustained clinical response in chronic psoriasis
The research center has extensive experience with placebo-controlled and active comparator trials, including open-label extension studies that assess the durability of therapeutic response. Semigallia SIA's specialized infrastructure supports the comprehensive evaluation of emerging oral treatment modalities, including novel kinase inhibitors and other targeted small molecule therapies designed to address the underlying inflammatory mechanisms of psoriasis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Semigallia SIA
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zasocitinib in Moderate-to-Severe Plaque Psoriasis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Takeda Development Center Americas Inc. | Phase III | Not Recruiting | May 2024 | Oct 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-05-07 | 2025-09-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.